RXO Inc. delivered strong 25% YoY revenue growth to $1.77B but failed to achieve earnings growth, with margins continuing to compress. Despite bullish market forecasts and a non-GAAP FWD EPS of $0.12, RXO's valuation appears unsustainably rich at 33x EV/EBITDA and 164x FWD P/E. Gross margin declined to 17% in Q2 from 21.2% last year, with negative operating cash flow and rising long-term debt signaling deteriorating fundamentals.